Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
4D Molecular Therapeutics (FDMT)
NASDAQ:FDMT
4D Molecular Therapeutics (FDMT) Stock Price & Analysis
78 Followers
FDMT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.32 - $26.49
Previous Close$17.61
Volume662.28K
Average Volume (3M)569.98K
Market Cap
$737.60M
Enterprise Value$552.83M
Total Cash (Recent Filing)$200.45M
Total Debt (Recent Filing)$15.68M
Price to Earnings (P/E)-5.2
Beta1.68
Next Earnings
Aug 10, 2023EPS Estimate
-$0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.38
Shares Outstanding33,260,378
10 Day Avg. Volume534,912
30 Day Avg. Volume569,976
Standard Deviation0.38
R-Squared0.12
Alpha-0.00153
Financial Highlights & Ratios
Price to Book (P/B)2.88
Price to Sales (P/S)1965.49
Price to Cash Flow (P/CF)-5.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue250.38
Enterprise Value/Gross Profit176.68
Enterprise Value/Ebitda-5.03
Forecast
1Y Price Target
$34.25Price Target Upside94.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
4D Molecular Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FDMT FAQ
What was 4D Molecular Therapeutics’s price range in the past 12 months?
4D Molecular Therapeutics lowest stock price was $5.32 and its highest was $26.49 in the past 12 months.
What is 4D Molecular Therapeutics’s market cap?
Currently, no data Available
When is 4D Molecular Therapeutics’s upcoming earnings report date?
4D Molecular Therapeutics’s upcoming earnings report date is Aug 10, 2023 which is in 74 days.
How were 4D Molecular Therapeutics’s earnings last quarter?
4D Molecular Therapeutics released its earnings results on May 10, 2023. The company reported -$0.88 earnings per share for the quarter, beating the consensus estimate of -$0.893 by $0.013.
Is 4D Molecular Therapeutics overvalued?
According to Wall Street analysts 4D Molecular Therapeutics’s price is currently Undervalued.
Does 4D Molecular Therapeutics pay dividends?
4D Molecular Therapeutics does not currently pay dividends.
What is 4D Molecular Therapeutics’s EPS estimate?
4D Molecular Therapeutics’s EPS estimate is -$0.8.
How many shares outstanding does 4D Molecular Therapeutics have?
4D Molecular Therapeutics has 41,885,380 shares outstanding.
What happened to 4D Molecular Therapeutics’s price movement after its last earnings report?
4D Molecular Therapeutics reported an EPS of -$0.88 in its last earnings report, beating expectations of -$0.893. Following the earnings report the stock price went up 1.847%.
Which hedge fund is a major shareholder of 4D Molecular Therapeutics?
Among the largest hedge funds holding 4D Molecular Therapeutics’s share is Viking Global Investors LP. It holds 4D Molecular Therapeutics’s shares valued at 68M.
---
4D Molecular Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.25 (94.49% Upside)
$34.25 (94.49% Upside)
Blogger Sentiment
Bullish
FDMT Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $13.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
136.69%
12-Months-Change
Fundamentals
Return on Equity
-42.68%
Trailing 12-Months
Asset Growth
-24.90%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
4D Molecular Therapeutics
4D Molecular Therapeutics Inc is a development stage precision gene therapy company. It engages in developing a broad pipeline of transformative gene therapy product candidates designed to treat patients suffering from lysosomal storage diseases, lung diseases, muscular dystrophies, and ophthalmic diseases. The AAV vectors are designed to provide targeted delivery by routine clinical routes, efficient transduction, reduced immunogenicity and resistance to pre-existing antibodies which enable to develop gene therapies.
---
Top 5 ETFs holding FDMT
iShares Core S&P Total U.S. Stock Market ETF
$746.22K
iShares NASDAQ US Biotechnology UCITS ETF
$348.96K
Schwab U.S. Broad Market ETF
$270.85K
Fidelity MSCI Health Care Index ETF
$262.59K
iShares Russell 3000 ETF
$133.25K
Up to five ETFs with an Outperform Smart Score that hold FDMT. The ETFs are listed according to market value of FDMT within the ETF
---
---